Study of STIM1 Membrane Expression
ConditionAutoimmune Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorUniversity Hospital, Brest
About this trial
The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.
This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
Eligibility criteria
Qualifiers
Diagnosis of one of the autoimmune diseases
Disqualifiers
Treatment with rituximab in the previous 12 months
Trial design
Treatments tested in this trial
- Not listed
Trial groups
670 Participants
are grouped into 18 trial groups18
Trial groupsSee each trial group below.
Sponsors and collaborators
Source ClinicalTrials.gov